A combination of serum markers for the early detection of colorectal cancer

Clinical Cancer Research

Volumn 16, Issue 24, 2010, Pages 6111-6121

  Wild, Norbert ^a   Andres, Herbert ^a   Rollinger, Wolfgang ^a   Krause, Friedemann ^a   Dilba, Peter ^a   Tacke, Michael ^a   Karl, Johann ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; FERRITIN; OSTEOPONTIN; P 53 ANTIBODY; SEPRASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOMA; ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CONTROL; EARLY DIAGNOSIS; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MIDDLE AGED; OCCULT BLOOD; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 78650403617     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0119     Document Type: Article

References (39)

1. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003;3:243-52.
2. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-society Task Force on Colorectal Cancer and the American College of Radiology. CA Cancer J Clin 2008;58:130-60.
3. U.S. Preventive Services Task Force, collaborators Calonge N, Petitti DB, Curry S, et al. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:627-37.
4. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007;16:1935-53.
5. Bustin SA, Gyselman VG, Williams NS, Dorudi S. Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. Br J Cancer 1999;79:1813-20.
6. Schiedeck TH, Wellm C, Roblick UJ, Broll R, Bruch HP. Diagnosis and monitoring of colorectal cancer by L6 blood serum polymerase chain reaction is superior to carcinoembryonic antigen-enzyme-linked immunosorbent assay. Dis Colon Rectum 2003;46:818-25.
7. Han M, Liew CT, Zhang HW, et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res 2008;14:455-60.
8. Ng EKO, Chong WWS, Jin H, et al. Differential expression of micro- RNAs in plasma of colorectal cancer patients: a potential marker for colorectal cancer screening. Gut 2009;58:1375-81.
9. Flamini E, Mercatali L, Nanni O, et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res 2006;12:6985-8.
10. Lofton-Day C, Model F, deVos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008;54:414-23.
11. DeVos T, Tetzner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009;55:1337-46.
12. Tänzer M, Balluff B, Distler J, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PloS One 2010;5:e9061. doi:10.1371/journal.pone.0009061
13. Karl J, Wild N, Tacke M, et al. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin Gastroenterol Hepatol 2008;6:1122-8.
14. Roessler M, Rollinger W, Palme S, et al. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res 2005;11:6550-7.
15. Roessler M, Rollinger W, Mantovani-Endl L, et al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cell Proteomics 2006;5:2092-101.
16. Thierolf M, Hagmann M-L, Pfeffer M, et al. Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100 A12 as potential cancer biomarker. Proteomics Clin Appl 2008;2:11-22.
17. Piñeiro-Sánchez ML, Goldstein LA, Dodt J, Howard L, Yeh Y, Chen W-T. Identification of the 170-kDa Melanoma membrane-bound gelatinase (Seprase) as a serine integral membrane protease. J Biol Chem 1997;272:7595-601.
18. Tibshirani B. Regression shrinkage and selection via the Lasso. J R Stat Soc B 1996;58:267-88.
19. 1 regularization path algorithm for generalized linear models. J R Stat Soc B 2007;69:659-77.
20. Zweig MH, Campell G. Receiver-operating characteristics plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;93:561-77.
21. Iwasa S, Okoka K, Chen W-T, et al. Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett 2005;227:229-36.
22. Carpelan-Homström M, Louhimo J, Stenman U-H, Alfthan H, Haglungd C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002;22:2311-6.
23. Carpelan-Holmström M, Louhimo J, Stenman U-H, Alfthan H, Järvinen H, Haglungd C. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 2004;66:296-302.
24. Kennedy A, Dong H, Chen D, Chen W-T. Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells. Int J Cancer 2009;124:27-35.
25. Henry LR, Lee H-O, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007;13:1736-41.
26. Chen D, Kennedy A, Wang J-Y, et al. Activation of EDTA-resistant gelatinases in malignant human tumors. Cancer Res 2006;66:9977-85.
27. Goldstein LA, Chen W-T. Identification of an alternatively spliced seprase mRNA that encodes a novel intracellular isoform. J Biol Chem 2000;275:2554-9.
28. Rohde F, Rimkus C, Friederichs J, et al. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer 2007;121:1717-23.
29. Irby RB, McCarthy SM, Yeatman TJ. Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 2004;21:515-23.
30. McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008;133:994-1005.
31. Fedarko NS, Jain A, Karadag A, van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6.
32. Kishida T, Sato J, Fujimori S, et al. Clinical significance of serum iron and ferritin in patients with colorectal cancer. J Gastroenterol 1994;29:19-23.
33. Li F, Kishida T, Kobayashi M. Serum iron and ferritin levels in patients with colorectal cancer in relation to the size, site, and disease stage of cancer. J Gastroenterol 1999;34:195-9.
34. Scholefield JH, Robinson MHE, Bostock K, Brown NS. Serum ferritin - screening test for colorectal cancer? Dis Colon Rectum 1998;41:1029-32.
35. Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-88.
36. Russo Am Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N for the TP53-CRC Collaborative Study Group. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005;23:7518-28.
37. Müller M, Meyer M, Schilling T, et al. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int J Oncol 2006;29:973-80.
38. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
39. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori S. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-8.